Candesartan Attenuates Diabetic Retinal Vascular Pathology by Restoring Glyoxalase-I Function

• DOI: 10.2337/db10-0552
• Publication Date: 2010-09-18T02:47:32Z
• Authors: Antonia G. Miller; Genevieve Tan; Katrina J. Binger; Raelene J. Pickering; Merlin C. Thomas; Ram H. Nagaraj; Mark E. Cooper; Jennifer L. Wilki...
• Keywords: 0301 basic medicine; Complications; 610; Tetrazoles; Polymerase Chain Reaction; Retina; Diabetes Mellitus, Experimental; Animals, Genetically Modified; Rats, Sprague-Dawley; 03 medical and health sciences; 616; Renin; Animals; Insulin; RNA, Messenger; Antihypertensive Agents; Diabetic Retinopathy; Biphenyl Compounds; Lactoylglutathione Lyase; Endothelial Cells; Flow Cytometry; Rats; 3. Good health; Benzimidazoles; Cattle; Female

OBJECTIVE Advanced glycation end products (AGEs) and the renin-angiotensin system (RAS) are both implicated in the development of diabetic retinopathy. How these pathways interact to promote retinal vasculopathy is not fully understood. Glyoxalase-I (GLO-I) is an enzyme critical for the detoxification of AGEs and retinal vascular cell survival. We hypothesized that, in retina, angiotensin II (Ang II) downregulates GLO-I, which leads to an increase in methylglyoxal-AGE formation. The angiotensin type 1 receptor blocker, candesartan, rectifies this imbalance and protects against retinal vasculopathy.

RESEARCH DESIGN AND METHODS Cultured bovine retinal endothelial cells (BREC) and bovine retinal pericytes (BRP) were incubated with Ang II (100 nmol/l) or Ang II+candesartan (1 μmol/l). Transgenic Ren-2 rats that overexpress the RAS were randomized to be nondiabetic, diabetic, or diabetic+candesartan (5 mg/kg/day) and studied over 20 weeks. Comparisons were made with diabetic Sprague-Dawley rats.

RESULTS In BREC and BRP, Ang II induced apoptosis and reduced GLO-I activity and mRNA, with a concomitant increase in nitric oxide (NO•), the latter being a known negative regulator of GLO-I in BRP. In BREC and BRP, candesartan restored GLO-I and reduced NO•. Similar events occurred in vivo, with the elevated RAS of the diabetic Ren-2 rat, but not the diabetic Sprague-Dawley rat, reducing retinal GLO-I. In diabetic Ren-2 rats, candesartan reduced retinal acellular capillaries, inflammation, and inducible nitric oxide synthase and NO•, and restored GLO-I.

CONCLUSIONS We have identified a novel mechanism by which candesartan improves diabetic retinopathy through the restoration of GLO-I.